ORIGINAL RESEARCH article

Front. Immunol.

Sec. Inflammation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1600421

This article is part of the Research TopicCholesterol, inflammation and immunityView all 6 articles

Hs-CRP/HDL-C Ratio as a Predictive Inflammatory-Lipid Marker for Sarcopenia: Evidence from NHANES 2015-2018

Provisionally accepted
Xin-Yan  GuoXin-Yan Guo1Li  Liang-WeiLi Liang-Wei2*
  • 1Tiantai Hospital of Traditional Chinese Medicine, Taizhou, Zhejiang, China
  • 2Second People's Hospital of Yuhang District, Hangzhou, China

The final, formatted version of the article will be published soon.

Objective: This study aimed to investigate the association between the high-sensitivity C-reactive protein/high-density lipoprotein cholesterol (Hs-CRP/HDL-C) ratio and sarcopenia among U.S. population by using composite marker integrating systemic inflammation and lipid metabolism.Method: This study included participants from the 2015-2018 of the National Health and Nutrition Examination Survey (NHANES). Sarcopenia was diagnosed based on the skeletal muscle index (SMI) by using dual-energy X-ray absorptiometry (DXA) technology. The Hs-CRP/HDL-C ratio was derived from laboratory examinations, was categorized into quartiles. Multivariate logistic regression models, adjusted for demographic and clinical covariates, were employed to assess the association between the Hs-CRP/HDL-C ratio and sarcopenia. Subgroup analysis and restricted cubic splines (RCS) were used to examine potential nonlinear relationships and threshold effects. Receiver operating characteristic (ROC) curve was used to evaluate the performance of the Hs-CRP/HDL-C ratio, Hs-CRP, and HDL-C indicators in predicting sarcopenia.Results: This study finally recorded 4,771 participants from NHANES from 2015-2018 for analysis. Elevated Hs-CRP/HDL-C ratios were significantly associated with an increased risk of sarcopenia, with a dose-response relationship observed across quartiles (p for trend <0.05). The fully adjusted model revealed that each unit increase in the Hs-CRP/HDL-C ratio corresponded to a 4% higher risk of sarcopenia (OR=1.04, 95% CI: 1.03–1.06, p=0.004). Participants in the highest quartile (≥3.54) of the Hs-CRP/HDL-C ratio had a 103% higher risk of sarcopenia compared to those in the lowest quartile (p=0.005). Subgroup analyses showed a stronger association in adults aged ≥40 years, with notable differences across races, especially among non-Hispanic Whites and other races. RCS model identified a non-linear association, with a threshold effect at a ratio of 2.58. The combined inflammatory and lipid markers Hs CRP/HDL-C showed stronger predictive performance (AUC: 0.694, 95% CI 0.672-0.716).Conclusion: The Hs-CRP/HDL-C ratio can serve as a practical indicator to identify individuals at higher risk of sarcopenia, capturing the combined effects of chronic inflammation and lipid metabolism issues. This ratio may be useful for early detection and prevention efforts targeting sarcopenia. However, more prospective research is needed to confirm these findings.Keywords: Sarcopenia, Hs-CRP/HDL-C ratio, Inflammation, Lipid metabolism, NHANES, Cross-sectional study

Keywords: hs-CRP/HDL-C ratio, Inflammation, Lipid Metabolism, NHANES, Cross-sectional study

Received: 26 Mar 2025; Accepted: 03 Jun 2025.

Copyright: © 2025 Guo and Liang-Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Li Liang-Wei, Second People's Hospital of Yuhang District, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.